A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 465-470

  Kuraoka, Kazuya ^a   Matsumura, Shunji ^a   Sanada, Yuichi ^a   Nakachi, Kei ^b   Imai, Kazue ^b   Eguchi, Hidetaka ^b   Matsusaki, Keisuke ^c   Oue, Naohide ^a   Nakayama, Hirofumi ^a   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^c Hofu Institute of Gastroenterology   (Japan)

Author keywords

Case control study; Development and progression of cancer; DR4; Gastric cancer; SNP

Indexed keywords

DNA; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADENOCARCINOMA; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; JAPAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; STOMACH NEOPLASMS;

EID: 24744456948     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.465     Document Type: Article

References (29)

1. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
2. Steller H: Mechanisms and genes of cellular suicide. Science 267: 1445-1449, 1995.
3. Thompson C: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
4. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 6: 529-535, 2000. (Pubitemid 30305902)
5. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG and Dyer MJ: Bc110 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35-45, 1999. (Pubitemid 29044151)
6. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211, 2001. (Pubitemid 32144287)
7. Songyang Z, Baltimore D, Cantley LC, Kaplan DR and Franke TF: Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci USA 94: 11345-11350, 1997. (Pubitemid 27451001)
8. Wang HG, Rapp UR and Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629-638, 1996. (Pubitemid 26386937)
9. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Perin V, Todesco M, De Iuliis A, Improta S, Sacco C, Gattei V, Grass HJ and Carbone A: The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 8 (Suppl. 2): 89-96, 1997.
10. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
11. Gura T: How TRAIL kills cancer cells, but not normal cells. Science 277: 768, 1997.
12. Griffith TS and Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998. (Pubitemid 28479189)
13. Singh TR, Shankar S, Chen X, Asim M and Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400, 2003. (Pubitemid 37139856)
14. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997. (Pubitemid 27161256)
15. Wu GS, Burns TF, McDonald ER III, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143, 1997.
16. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998. (Pubitemid 28406815)
17. Hymowitz SG, Christinger HW, Fuh G, et al: Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4: 563-5671, 1999.
18. Fisher MJ, Virmani AK, Wu L, et al: Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7: 1688-1697, 2001. (Pubitemid 32708637)
19. Bodmer JL, Holler N, Reynard S, et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-243, 2000.
20. Kim K, Fisher MJ, Xu SQ and El-Deiry WS: Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346, 2000. (Pubitemid 30111448)
21. Li LC, Chui RM, Sasaki M, et al: A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60: 873-876, 2000. (Pubitemid 30129518)
22. Wu MS, Huang SP, Chang YT, et al: Association of the -160 C - a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 94: 1443-1448, 2002.
23. Kuraoka K, Oue N, Yokozaki H, Kitadai Y, Ito R, Nakayama H and Yasui W: Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol 23: 421-427, 2003.
24. Xie D, Shu XO, Deng Z, et al: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92: 412-417, 2000. (Pubitemid 30154823)
25. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC and Henderson BE: Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61: 8393-8394, 2001. (Pubitemid 33131112)
26. Kuraoka K, Nakachi K, Yasui W, et al: A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 107: 593-596, 2003. (Pubitemid 37296120)
27. Matsumura S, Oue N, Yasui W, et al: A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131: 19-25, 2005.
28. Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR and Wu X: Death receptor 4 and bladder cancer risk. Cancer Res 63: 1157-1159, 2003. (Pubitemid 36348687)
29. Yokozaki H: Distribution of germline BAT-40 poly-adenine tract microsatellite variants in the Japanese. Int J Mol Med 6: 445-448, 2000.